Melflufen: post-hoc subgroup analyses and the US FDA Oncologic Drugs Advisory Committee.

Cliff, Edward R Scheffer; Janakiram, Murali; Kesselheim, Aaron S

Cliff, Edward R Scheffer; Janakiram, Murali; Kesselheim, Aaron S.

Afiliação

Cliff ERS; Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA; Harvard Medical School, Harvard University, Boston, MA, USA. Electronic address: ecliff@bwh.harvard.edu.
Janakiram M; Division of Myeloma, Department of Hematology and Hematopoietic cell transplantation, City of Hope National Medical Center, Duarte, CA, USA.
Kesselheim AS; Program On Regulation, Therapeutics And Law, Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital, Boston, MA 02120, USA; Harvard Medical School, Harvard University, Boston, MA, USA.

Lancet Haematol ; 10(5): e314-e317, 2023 05.

Article em En | MEDLINE | ID: mdl-37142342

Assuntos

Comitês Consultivos; Melfalan; Estados Unidos; Humanos; Oncologia; Fenilalanina

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Comitês Consultivos / Melfalan Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Lancet Haematol Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google